



Effect of history of tuberculosis on specificity of Xpert MTB/RIF

To the Editor:

Tuberculosis (TB) is the leading cause of mortality among infectious diseases. In 2018, 1.5 million people died due to TB [1]. Early diagnosis of TB is key in achieving WHO End TB targets, and molecular diagnostic tests have been developed. However, molecular tests cannot differentiate between viable and non-viable bacteria [2, 3], leading to challenges in the interpretation of positive test results in patients with recent TB.

Xpert MTB/RIF (“Xpert”, Cepheid, Sunnyvale, CA, USA), a widely used molecular diagnostic, amplifies sequences of the *rpoB* gene specific to *Mycobacterium tuberculosis* complex bacteria [4, 5]. Xpert has a high specificity estimated as 98% (95% CI 97–99) in a meta-analysis [6]. Growing evidence from case reports or small studies and one larger study by G. Theron and co-workers suggests a reduced Xpert specificity among patients with TB history [2, 7–9]. The rate of Xpert false-positives is higher, the more recent the history of TB [10]. This poses a clinical dilemma: while patients with recent TB have a high risk of reinfection or relapse, they may also have a high risk of a false-positive result [2, 8, 10].

To inform policy and clinical practice, we assessed the effect of TB history on the specificity of Xpert by time since the previous TB episode in settings with different levels of HIV-co-infection [11] in 16 studies collated by FIND (Foundation of Innovative New Diagnostics, Geneva, Switzerland). While studies were carried out under different protocols, all used Xpert and a common reference standard with liquid and solid cultures that was standardised across studies.

We included all presumptive patients 18 years or older with Xpert and cultures performed. Patients were recruited in 10 countries (Belarus, Cambodia, Georgia, India, Italy, Moldova, Peru, South Africa, Vietnam and Zimbabwe) between 9 June 2011 and 6 March 2018. We considered Xpert results for the first sample only. Patients with missing Xpert results were excluded from the analysis.

The reference standard was based on Lowenstein Jensen (LJ) and Mycobacterium Growth Indicator Tube (Bactec MGIT; BD Microbiology Systems, Cockeysville, MD, USA). Chest radiographs were considered compatible with TB, if the attending clinician rated the radiograph at least as likely for TB. We estimated the specificity of Xpert as the proportion of Xpert negative out of the culture-negative patients. Time since previous TB treatment was calculated as the difference in dates between enrolment and the previous treatment completion. We estimated the specificity of Xpert using logistic regression with a random effect to account for clustering by study. All analyses were performed using Stata version 15 (stataCorp LLC, TX, USA).

A total of 11 583 patients had Xpert and culture results. We excluded 1627 (1615 missing Xpert results, 12 below 18 years old), leaving 10 053 patients for the analysis. Of these, 59% (5900/10 053) had a positive culture and 55% were positive on Xpert. Overall, 16% (1630/10 053) of patients had a history of TB. The median time since previous TB treatment was 3 years (interquartile range (IQR) 0.0–6 years). Patients with TB history tended to be older (median age 39 (IQR 31–48) *versus* 35 (IQR 26–49) years), HIV positive and resistant to rifampicin.

False-positive Xpert results were observed in 6.5% (95% CI 2.8–13.7) of patients with TB history and 2% (95% CI 0.6–5.6) without TB history. In patients without previous TB, specificity was estimated as 98.0% (95% CI 96.0–99.7; 3095/3164), while in those with, it was 93.5% (95% CI 80.4–98.1; 465/501). Among the 803 participants with a TB episode within 2 years of testing, the specificity of Xpert was 92.2%



@ERSpublications

Specificity of Xpert MTB/RIF was lower in those with tuberculosis (TB) history compared to those without TB history and specificity increased as time since previous TB increased <https://bit.ly/2W4hWfX>

Cite this article as: Haraka F, Schumacher SG, Ross A, *et al.* Effect of history of tuberculosis on specificity of Xpert MTB/RIF. *Eur Respir J* 2020; 56: 2000343 [<https://doi.org/10.1183/13993003.00343-2020>].




FIGURE 1 Xpert MTB/RIF specificity by time since previous tuberculosis episode. Specificity was estimated using logistic regression with a random effect to account for clustering by study. Error bars represent 95% confidence intervals.

(95% CI 81–97). The specificity increased with time since the previous TB. Between 2 and 5 years (373 participants), the specificity was 99.0% (95% CI 86–100) and above 5 years (454 participants), 98.6% (95% CI 85.4–99.8). The rate of false positivity for TB detection was similar in both groups in patients with rifampicin resistance regardless of TB history. Of 247 patients with false-positive results, 109 had chest radiograph results, of which 75% were compatible with active TB. Patients with a non-compatible radiograph were more likely to have a false-positive Xpert result with an odds ratio of 4.9 (95% CI 2–11) adjusting for TB history, HIV, age and sex.

This study represents the largest dataset to date to assess the effect of TB history on the specificity of Xpert for TB. The specificity of Xpert was lower in those with TB history compared to those without it and increased as time since previous TB increased (figure 1). In patients with TB history within 2 years, specificity was reduced. False-positive was associated with negative chest radiograph, even when adjusted for TB history and HIV, consistent with previous findings [12]. This suggests that a negative chest radiograph could aid in deciding whether to start a patient with a positive Xpert result and recent TB history on therapy. This might be a viable strategy in patients without HIV. In HIV patients, the risk of not treating a patient who may truly have TB might outweigh the risk of overtreatment. These results only provide an association and not causation. However, the decreased specificity in patients with recent TB history is coupled with increased sensitivity, as shown with Xpert MTB/RIF Ultra [10], which supports the causal link. A causal link is further supported by an association between false-positive results and decreasing bacterial load in those with TB history. High cycle threshold values (Ct) predict false Xpert positivity; however, the discriminatory power of Ct values in predicting false-positives remains minimal [9]. A study showed that patients with false-positive Xpert remained healthy and asymptomatic after 17 months of follow-up [12]. However, PET-CT showed positivity consistent with active disease at the end of therapy [2, 8], suggesting Xpert false positivity might not stem only from non-viable bacteria alone but could also be related to viable bacteria still present after a patient is clinically cured.

A limitation of our study was that Ct values for Xpert were not reported and that clinical outcome data were not available. Study strengths include the size of the dataset with a common reference standard. Data from different settings suggest likely generalisability. The overall specificity of Xpert in our study of 98% is identical with the pooled specificity reported in a recent Cochrane review including 95 studies [6].

Our results may have implications for the design of diagnostic algorithms in patients with TB history, particularly if the prior episode was within 2 years. Consideration of other conditions and careful clinical decision before treatment initiation in this group is important. The impact of false-positive results on patient outcomes remains a relevant question for future studies and modelling studies, such as the one by KENDALL *et al.* [13] for Xpert Ultra, should weigh the impact of likely overtreatment among patients with previous TB history in different epidemiological settings. Importantly, while our findings pertain directly to Xpert, similar results should be expected with other molecular TB assays. In conclusion, Xpert specificity is reduced among patients with previous TB history, and this reduction is greater among those with TB in the last 2 years.

Frederick Haraka^{1,2,3}, Samuel G. Schumacher⁴, Amanda Ross^{2,3}, Anna Mantsoki⁴, Sebastien Gagneux^{1,2,3}, Klaus Reither^{1,2,3,6} and Claudia M. Denking^{4,5,6}

¹Ifakara Health Institute, Bagamoyo, Tanzania. ²Swiss Tropical and Public Health Institute, Basel, Switzerland. ³University of Basel, Basel, Switzerland. ⁴Foundation for Innovative New Diagnostics, Geneva, Switzerland. ⁵Division of Tropical Medicine, Center of Infectious Diseases, University Hospital Heidelberg, Heidelberg, Germany. ⁶Equal contributions.

Correspondence: Samuel G. Schumacher, Foundation for Innovative New Diagnostics, Campus Biotech, Chemin des Mines 9, Geneva 1202, Switzerland. E-mail: samuel.schumacher@finddx.org

Received: 17 Feb 2020 | Accepted after revision: 22 April 2020

Acknowledgements: We acknowledge all study teams, FIND data team and Ramadhani Abdul, a statistician at Ifakara Health Institute, for their support during data extraction and management.

Conflict of interest: F. Haraka has nothing to disclose. S.G. Schumacher reports grants from the Bill and Melinda Gates Foundation during the conduct of the study, and is an employee of FIND. A. Ross has nothing to disclose. A. Mantsoki has nothing to disclose. S. Gagneux has nothing to disclose. K. Reither has nothing to disclose. C.M. Denkinger reports grants from the Bill and Melinda Gates Foundation, during the conduct of the study; and is a former employee of FIND.

Support statement: This work was based on data generated through support by the Bill and Melinda Gates Foundation OPP1034061, OPP1105925 and then OPP1169706. Funding information for this article has been deposited with the Crossref Funder Registry.

References

- 1 World Health Organization. Global Tuberculosis Report. Geneva, World Health Organization, 2019.
- 2 Shenai S, Ronacher K, Malherbe S, *et al*. Bacterial loads measured by the Xpert MTB/RIF assay as markers of culture conversion and bacteriological cure in pulmonary TB. *PLoS One* 2016; 11: e0160062.
- 3 Kayigire XA, Friedrich SO, Venter A, *et al*. Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity. *J Clin Microbiol* 2013; 51: 1894–1898.
- 4 Blakemore R, Story E, Helb D, *et al*. Evaluation of the analytical performance of the Xpert MTB/RIF assay. *J Clin Microbiol* 2010; 48: 2495–2501.
- 5 Helb D, Jones M, Story E, *et al*. Rapid detection of *Mycobacterium tuberculosis* and rifampin resistance by use of on-demand, near-patient technology. *J Clin Microbiol* 2010; 48: 229–237.
- 6 Horne DJ, Kohli M, Zifodya JS, *et al*. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database Syst Rev* 2019; 6: CD009593.
- 7 Friedrich SO, Rachow A, Saathoff E, *et al*. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. *Lancet Respir Med* 2013; 1: 462–470.
- 8 Malherbe ST, Shenai S, Ronacher K, *et al*. Persisting positron emission tomography lesion activity and *Mycobacterium tuberculosis* mRNA after tuberculosis cure. *Nat Med* 2016; 22: 1094–1100.
- 9 Theron G, Venter R, Calligaro G, *et al*. Xpert MTB/RIF results in patients with previous tuberculosis: can we distinguish true from false positive results? *Clin Infect Dis* 2016; 62: 995–1001.
- 10 Dorman SE, Schumacher SG, Alland D, *et al*. Xpert MTB/RIF Ultra for detection of *Mycobacterium tuberculosis* and rifampicin resistance: a prospective multicentre diagnostic accuracy study. *Lancet Infect Dis* 2018; 18: 76–84.
- 11 Steingart KR, Schiller I, Dendukuri N. In reply to “False-positive Xpert(R) MTB/RIF assays in previously treated patients”. *Int J Tuberc Lung Dis* 2015; 19: 366–367.
- 12 Theron G, Venter R, Smith L, *et al*. False-positive Xpert MTB/RIF results in retested patients with previous tuberculosis: frequency, profile, and prospective clinical outcomes. *J Clin Microbiol* 2018; 56: e01696-17.
- 13 Kendall EA, Schumacher SG, Denkinger CM, *et al*. Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: a modeling study *PLoS Med* 2017; 14: e1002472.

Copyright ©ERS 2020